Brookstone Capital Management Buys 67,034 Shares of Boston Scientific Corporation $BSX

Key Points

• Brookstone Capital Management increased its Boston Scientific stake by 36.6% in Q1, buying 67,034 additional shares and bringing its total holding to 250,231 shares worth about $15.7 million.
• Insiders were also buying: directors David C. Habiger and Cheryl Pegus both purchased shares in May, and insider buying totaled 9,800 shares worth $554,012 over the last three months.
• Boston Scientific’s fundamentals and outlook remain mixed despite solid earnings, with the company beating quarterly EPS and revenue estimates and authorizing a $5 billion share buyback, while analysts maintain a “Moderate Buy” consensus with an average target price of $85.08.

Brookstone Capital Management boosted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 36.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 250,231 shares of the medical equipment provider's stock after purchasing an additional 67,034 shares during the period. Brookstone Capital Management's holdings in Boston Scientific were worth $15,702,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BSX. Claret Asset Management Corp boosted its stake in shares of Boston Scientific by 4.4% during the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider's stock valued at $234,000 after purchasing an additional 102 shares during the period. Cary Street Partners Investment Advisory LLC increased its stake in shares of Boston Scientific by 5.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider's stock worth $206,000 after buying an additional 103 shares during the period. Outfitters Financial LLC raised its holdings in Boston Scientific by 0.5% during the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider's stock valued at $2,291,000 after buying an additional 110 shares during the last quarter. Fayez Sarofim & Co raised its holdings in Boston Scientific by 2.1% during the 3rd quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider's stock valued at $520,000 after buying an additional 111 shares during the last quarter. Finally, Natural Investments LLC boosted its position in Boston Scientific by 2.9% during the 4th quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider's stock valued at $384,000 after buying an additional 112 shares during the period. Institutional investors own 89.07% of the company's stock.

Insider Buying and Selling at Boston Scientific

In other news, Director David C. Habiger bought 2,250 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the acquisition, the director owned 13,878 shares of the company's stock, valued at approximately $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Cheryl Pegus bought 1,770 shares of the firm's stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BSX. Truist Financial cut their price target on shares of Boston Scientific from $85.00 to $64.00 and set a "buy" rating on the stock in a report on Thursday, June 4th. Oppenheimer set a $90.00 target price on Boston Scientific in a research note on Thursday, April 23rd. BTIG Research restated a "buy" rating and set a $65.00 price target on shares of Boston Scientific in a report on Tuesday, June 16th. Wall Street Zen lowered Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, March 28th. Finally, The Goldman Sachs Group set a $71.00 price objective on Boston Scientific in a report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Boston Scientific has an average rating of "Moderate Buy" and an average target price of $85.08.

Boston Scientific Trading Up 0.0%

NYSE:BSX opened at $45.30 on Monday. The company has a 50-day moving average price of $54.71 and a 200-day moving average price of $72.83. The stock has a market cap of $67.33 billion, a price-to-earnings ratio of 18.95, a P/E/G ratio of 0.87 and a beta of 0.56. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 12 month low of $44.44 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.20 billion for the quarter, compared to analysts' expectations of $5.19 billion. During the same quarter in the previous year, the company earned $0.75 earnings per share. Boston Scientific's quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific announced that its Board of Directors has approved a share buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are often an indication that the company's management believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.